MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

Go back to MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
Mannkind Corporation (NASDAQ: MNKD) Delayed: 4.06 +0.10 (2.53%)
Previous Close $3.96    52 Week High $2.51 
Open $3.92    52 Week Low $0.41 
Day High $4.10    P/E N/A 
Day Low $3.92    EPS $-0.64 
Volume 2,807,582       

Mannkind Corporation (NASDAQ: MNKD) Delayed: 4.06 +0.10 (2.53%)
Previous Close $3.96    52 Week High $2.51 
Open $3.92    52 Week Low $0.41 
Day High $4.10    P/E N/A 
Day Low $3.92    EPS $-0.64 
Volume 2,807,582